Anthem Biosciences Q1FY27: Revenue falls 22.6% YoY to Rs 4,182 Cr
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Midcap 150 and 0.3 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anthem Biosciences Q1FY27 consolidated revenue fell 22.6% YoY to Rs 4,182 Mn from Rs 5,402 Mn. EBITDA was Rs 1,755 Mn at 39.6% margins, down 18.1% YoY. PAT declined 11.7% YoY to Rs 1,199 Mn at 27.1% margins. CRDMO revenue dropped 24.7% YoY to Rs 3,408 Mn. Management attributed the decline to timing shifts in customer deliveries and expects stronger performance in the second half of FY27.
Sharp YoY revenue and profit decline on delivery timing issues. Management guides for H2 recovery, but near-term stock sentiment may remain cautious.